Skip to main content
Glama

Interpro

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Beyond the read-only/idempotent annotations, the description discloses critical behaviors: it returns `figi_candidates` on ambiguity, lists `unresolved` identifiers explicitly, labels each identifier with its source, degrades gracefully when GLEIF/OpenFIGI are unavailable, and cascades through multiple internal lookups. This is exactly the contextual transparency an agent needs.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long but structured with examples, supported types, and important edge-case notes. It is front-loaded with the core use case and the 'Use FIRST' directive. Some wording is dense, but every paragraph serves a real purpose for a complex, multi-backend tool.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Despite having no output schema, the description thoroughly covers return behavior, ambiguity handling, unresolved identifiers, source labeling, and fallback semantics. It also explains why ambiguous bond matches are the correct answer, giving an agent enough context to invoke and interpret the tool correctly.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Although schema coverage is 100%, the description significantly expands parameter meaning: it details accepted inputs for company (ticker, CIK, ISIN, or name), clarifies drug input semantics, and warns against passing full noun phrases like security-class suffixes. The concrete examples and explicit 'ENTITY NAME ONLY' guidance add substantial value beyond the schema.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with a clear verb and resource: resolving user-spoken names into canonical/official identifiers. It enumerates concrete examples, supported entity types, and the identifier domains (CIK, ticker, LEI, FIGI, RxCUI), making its purpose unmistakable and easy to distinguish from sibling tools like entity_profile or search_entries.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly says 'Use FIRST whenever you have a name but need an ID,' providing direct usage guidance. It stops short of explicitly naming alternatives or saying when not to use it, but the instruction is strong enough to route an agent correctly.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Interpro toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.6/5.0
Disambiguation2/5

Several tool clusters have fuzzy boundaries: ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded, deep_research, discover_tools, and suggest_questions all overlap on 'find and query data,' while the five polymarket_* tools plus bet_research form a heavily overlapping prediction-market cluster. The three genuine InterPro tools are clear, but an agent would frequently struggle to pick the right meta-tool.

Naming Consistency3/5

Most tools follow a readable snake_case verb-first pattern like compare_entities, resolve_entity, and validate_claim. However, bare verbs (remember, forget, recall), product-prefixed nouns (pipeworx_feedback, pipeworx_trending), and variant suffixes (ask_pipeworx_beta, ask_pipeworx_grounded) break the pattern enough to feel inconsistent.

Tool Count2/5

34 tools is well above the typical well-scoped range, and many tools duplicate or partially overlap each other's functionality. The count is further inflated by unrelated domains—AI visibility, prediction markets, memory, subscriptions, package auditing—bundled into a server nominally named 'Interpro.'

Completeness2/5

The InterPro subset (search_entries, get_entry, entries_for_protein) is minimal and lacks obvious protein/proteome-level operations, while the rest of the server covers so many unrelated domains that no single domain has clear end-to-end coverage. The Pipeworx query side is broad, but the overall surface feels like several incomplete toolsets merged rather than one complete product.

Resources